Business
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
Q4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent
About this update from Trisalus Life Sciences, Inc.
[{"type":"text","content":"\n\nQ4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023\n\n\n\nFull year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023\n\n\n\nQ4 Operating Cash Flow of approximately ($5.6) million is a notable improvement compared to ($10.8) million in Q3\n\n\n\nCompany expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of 2025\n\n\n\nCall Scheduled for Thursday, March 27, 2025, at 8:00 a.m. ET\n\n\n DENVER--(BUSINESS WIRE)--\nTriSalus Life Sciences® Inc. (Nasdaq: TLSI), is announcing preliminary unaudited fourth quarter and full year 2024 financial results and details of the upcoming conference call.\n\n\nPreliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results\n\n\nFull financial results for the year ended December 31, 2024 are in the process of being finalized, however initial and preliminary results show revenue, driven solely by the TriNav® Infusion System, of approximately $8.3 million for the fourth quarter of 2024. This represents growth of approximately 44% versus the fourth quarter of 2023.\n\n\nFor the full year 2024, revenue was approximately $29.4 million. This represents growth of approximately 59% versus the full year 2023. This strong momentum is expected to continue in 2025 and, consistent with previously announced guidance, revenue is expected to grow in excess of 50% in 2025.\n\n\nOperating Cash Flow in the fourth quarter of 2024 was approximately ($5.6) million, reflecting a notable improvement compared to the previous quarter amount of ($10.8) million. Consistent with previously announced guidance, the Company expects to achieve positive full year EBITDA in 2025 and positive cash flow during the second half of 2025.\n\n\nCash and Cash Equivalents were approximately $8.5 million as of December 31st, 2024. We expect to qualify for an additional $10 million tranche of our existing debt agreement with OrbiMed in the first quarter of 2025 and expect, with the additional $10 million, to have sufficient liquidity to fund operations through 2025.\n\n\nConference Call Details\n\n\nThe company will host a conference call and webcast on March 27, 2025, at 8:00 a.m. ET to discuss financial results for the fourth quarter and full year ended December 31, 2024, and provide a busine...